Category

News
A decade ago, patients with newly diagnosed multiple myeloma typically survived 3 to 5 years. However, the development of highly effective therapies — including proteasome inhibitors, immunomodulatory drugs and monoclonal antibodies — has greatly improved outcomes. In addition to extending survival, these newer agents are associated with considerably less toxicity. “We not only have this...
Continue Reading
A leading international consultant haematologist in the treatment of multiple myeloma, Professor Saad Z. Usmani, Chief of Plasma Cell Disorders Program and Director of Clinical Research in Hematologic Malignancies at the Levine Cancer Institute and Carolinas HealthCare System in Charlotte, US, believes the results of the combined analysis from the SIRIUS and the GEN5011 trials...
Continue Reading
Kiwi researchers have stumbled upon what could be a promising agent against an incurable blood cancer. Based on just-published findings, Otago University researchers are keen to know whether a decades-old antibiotic and others like it might offer hope for people living with myeloma. Around 360 Kiwis each year are diagnosed with the disease, which is a...
Continue Reading
U.S. Food and Drug Administration (FDA) Commissioner Scott Gottlieb, MD, expressed concern in October over the price of chimeric antigen receptor (CAR) T-cell therapies. In an interview with STAT News during a session at the Milken Institute’s Future of Health Summit 2018, Dr. Gottlieb warned that the failure to develop CAR T-cell therapy payment structures could slow...
Continue Reading
Cancer remains the second-leading cause of death in the United States. This year, an estimated 1.7 million new cases will be diagnosed, with nearly 610,000 people expected to die from the disease, according to the National Cancer Institute. Fortunately, several recent cancer treatments show considerable promise. Among them is Chimeric Antigen Receptor (CAR) T cell...
Continue Reading
Greetings.  Spring is in the air and the end of the year is fast approaching. Save the Date    The final patient seminar and end of year function will be Wednesday, 12 December 2018.   Details to follow soon. Website We are continually adding fresh content and hope that people are finding the articles of interest. ...
Continue Reading
The U.S. Food and Drug Administration (FDA) has authorized the next-generation sequencing (NGS)–based clonoSEQ assay for the measurement of minimal residual disease (MRD) in patients with acute lymphocytic leukaemia (ALL) or multiple myeloma (MM). This is the first NGS-based test approved for this purpose. The FDA’s approval was based on results from a retrospective analysis...
Continue Reading
Clinical Question Among patients with multiple myeloma, is bisphosphonate therapy associated with lower rates of mortality, vertebral fractures, nonvertebral fractures, and skeletal-related events compared with placebo or no treatment? Bottom Line Among patients with myeloma, bisphosphonates were associated with lower rates of pathological fractures and skeletal-related events compared with placebo or no treatment. Direct meta-analysis...
Continue Reading
Compared with standard therapy of lenalidomide and dexamethasone, the addition of carfilzomib improved survival, without increasing the risk of adverse events (AEs) in patients with relapsed or refractory multiple myeloma (MM), according to final results from the phase III ASPIRE trial.1 “At interim analysis … the addition of carfilzomib significantly improved progression-free survival (PFS) compared...
Continue Reading
Multiple myeloma accounts for approximately 10% of hematologic malignancies. The diagnosis requires ≥10% clonal bone marrow plasma cells or a biopsy proven plasmacytoma plus evidence of one or more multiple myeloma defining events: CRAB (hypercalcemia, renal failure, anemia, or lytic bone lesions) features felt related to the plasma cell disorder, bone marrow clonal plasmacytosis ≥60%, serum involved/uninvolved...
Continue Reading
1 25 26 27 28 29 37

Floor 7, 90 The Terrace
Wellington Central
New Zealand